Porton Advanced’s End-to-End CDMO Solutions Accelerates IND Approval of Tasly’s Innovative Dual-Targeting CAR-T Therapy
Porton Advanced Supports Immunofoco’s Second IND Clearance from China’s CDE for EpCAM CAR-T Therapy in Solid Tumors
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T‑Cell Therapy Development
Porton Advanced Congratulates Esteemed Partner Lion TCR on IND Approval from NMPA for mRNA TCR-T Cell Therapy GZL-016 in Hepatitis B-Related Liver Cancer
Porton Advanced and Geneseed Biotech Enter into Strategic Collaboration to Focus on Advancing circRNA Innovative Therapeutics
Porton Advanced introduces the MaxCyte ExPERT GTx Flow Electroporation instrument, continuing to provide customers with end-to-end cell and gene therapy CRO & CDMO services
